DOR/ISL for HIV

"Patients with no doravirine resistance-associated mutations often find relief through the use of DOR/ISL. This drug combination is also useful in treating conditions like treatment failure, antiretroviral therapy naivety and other forms of antiretroviral therapies."

"No, this trial has closed its recruitment process. It was first posted on November 26th 2020 and the last update occured on October 13th 2022. For those seeking alternative trials, there are 853 studies that seek patients with infections as well as 21 DOR/ISL clinical studies which remain open to participants."

"This medical study is enrolling patients from four different sites, such as Emory Children's Center (Site 1805) in Atlanta and Duke University ( Site 1807) in Durham. Additionally, the Children's National Medical Center ( Site 1816) located in Washington is also participating."

"According to Merck Sharp & Dohme Corp., the primary metric of this trial is Apparent total clearance from plasma (CL/F) at Pre-dose, and 4 and 24 hours post-dose on Day 28. Additionally, secondary measurements include Percentage of VS participants with HIV-1 RNA ≥50 copies/mL determined by an Abbott Real Time PCR assay; Percentage of TN participants with HIV-1 RNA <50 copies/mL established via an Abbott Real Time PCR assay; as well as Change from baseline in CD4+ T-cells in VS participants evaluated through a central laboratory."

"In terms of safety, our team has assigned the drug DOR/ISL a score of 2. This is based on data from its Phase 2 trial which suggests that it is safe to use but there are yet no confirmed benefits associated with it."

"As of now, 21 studies surrounding DOR/ISL are underway in 146 cities and 27 nations. These efforts began back in 2014 when Merck Sharp & Dohme LLC conducted a Phase 3 clinical trial involving 769 participants. Subsequently, 19 more trials have been realized since the initial effort concluded."

"Presently, 21 clinical trials concerning DOR/ISL are underway. Of these studies, 9 have advanced to Phase 3 and they are mainly found in Cape Town, Western Cape. However, 348 locations globally provide this treatment regimen."

"The latest edit to this medical trial's information on clinicaltrials.gov indicates that it is not accepting new participants, despite initially being posted in November 2020. Nevertheless, 874 other trials are currently seeking volunteers for their research efforts."